Dyne Therapeutics Q2 net loss widens

Dyne Therapeutics

28/07/2025 21:28

Overview

Dyne Therapeutics  Q2 net loss widens

Co extends cash runway into Q3 2027, supporting multiple clinical milestones

Dyne strengthens financial position with public offering and loan facility

Outlook

Dyne expects cash runway to extend into Q3 2027

Company plans U.S. Accelerated Approval submissions in 2026

Dyne anticipates DYNE-251 commercial launch in early 2027

Company pursuing approval pathways outside U.S. for DYNE-101 and DYNE-251

Result Drivers

R&D INVESTMENT - Increased R&D expenses were $99.2 million

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
Miss
-$0.97
-$0.95 (15 Analysts)
Q2 Net Income
Beat
-$110.86 mln
-$112.60 mln (13 Analysts)
Q2 Operating Income
Beat
-$115.79 mln
-$136.50 mln (13 Analysts)
Q2 Basic EPS
-$0.97
Q2 Operating Expenses
$115.79 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Dyne Therapeutics Inc is $44.50, about 77.6% above its July 25 closing price of $9.95

Press Release: ID:nGNXwYFSr

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)